,SARS-CoV-2 Mpro,

Jin Ou1, Eric M Lewandowski2, Yanmei Hu3

  • 1Department of Biology, School of Arts and Sciences, The Catholic University of America, Washington, Washington DC, United States of America.

PLoS pathogens
|August 31, 2023
PubMed
概括

耐药SARS-CoV-2变种对COVID-19治疗构成威胁. 酵母测定主要蛋白酶 (Mpro) 中快速识别的突变,使其对尼尔马特雷尔维尔产生耐药性,有助于描述潜在的抗病毒耐药性.